Endometrial Cancer
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma (LEAP-001)(MK-7902-001-00)
- Details
ClinicalTrials.gov ID:
NCT03884101
Diagnosis Type:
NA
USOR Number:
- Address
6025 Lake Rd, Suite 110
Woodbury, MN 55125
P: (651) 735-7414